Literature DB >> 7644533

Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion.

M Buerke1, T Murohara, C Skurk, C Nuss, K Tomaselli, A M Lefer.   

Abstract

In the present study, the cardioprotective effects of insulin-like growth factor I (IGF-I) were examined in a murine model of myocardial ischemia reperfusion (i.e., 20 min + 24 hr). IGF-I (1-10 micrograms per rat) administered 1 hr prior to ischemia significantly attenuated myocardial injury (i.e., creatine kinase loss) compared to vehicle (P < 0.001). In addition, cardiac myeloperoxidase activity, an index of neutrophil accumulation, in the ischemic area was significantly attenuated by IGF-I (P < 0.001). This protective effect of IGF-I was not observed with des-(1-3)-IGF-I. Immunohistochemical analysis of ischemic-reperfused myocardial tissue demonstrated markedly increased DNA fragmentation due to programmed cell death (i.e., apoptosis) compared to nonischemic myocardium. Furthermore, IGF-I significantly attenuated the incidence of myocyte apoptosis after myocardial ischemia and reperfusion. Therefore, IGF-I appears to be an effective agent for preserving ischemic myocardium from reperfusion injury and protects via two different mechanisms--inhibition of polymorphonuclear leukocyte-induced cardiac necrosis and inhibition of reperfusion-induced apoptosis of cardiac myocytes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7644533      PMCID: PMC41280          DOI: 10.1073/pnas.92.17.8031

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  Cell death and control of cell survival in the oligodendrocyte lineage.

Authors:  B A Barres; I K Hart; H S Coles; J F Burne; J T Voyvodic; W D Richardson; M C Raff
Journal:  Cell       Date:  1992-07-10       Impact factor: 41.582

2.  Apoptosis. The role of the endonuclease.

Authors:  M J Arends; R G Morris; A H Wyllie
Journal:  Am J Pathol       Date:  1990-03       Impact factor: 4.307

Review 3.  Actions of insulin-like growth factors.

Authors:  E R Froesch; C Schmid; J Schwander; J Zapf
Journal:  Annu Rev Physiol       Date:  1985       Impact factor: 19.318

4.  An improved procedure for serum creatine phosphokinase determination.

Authors:  S B Rosalki
Journal:  J Lab Clin Med       Date:  1967-04

5.  Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets.

Authors:  M W Radomski; R M Palmer; S Moncada
Journal:  Br J Pharmacol       Date:  1987-09       Impact factor: 8.739

6.  Time course of endothelial dysfunction and myocardial injury during myocardial ischemia and reperfusion in the cat.

Authors:  P S Tsao; N Aoki; D J Lefer; G Johnson; A M Lefer
Journal:  Circulation       Date:  1990-10       Impact factor: 29.690

7.  Nitric oxide synthesis inhibitor prevents vasodilation by insulin-like growth factor I.

Authors:  J Haylor; I Singh; A M el Nahas
Journal:  Kidney Int       Date:  1991-02       Impact factor: 10.612

8.  Mediation of cardioprotection by transforming growth factor-beta.

Authors:  A M Lefer; P Tsao; N Aoki; M A Palladino
Journal:  Science       Date:  1990-07-06       Impact factor: 47.728

9.  Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker.

Authors:  P P Bradley; D A Priebat; R D Christensen; G Rothstein
Journal:  J Invest Dermatol       Date:  1982-03       Impact factor: 8.551

10.  Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium.

Authors:  K M Mullane; R Kraemer; B Smith
Journal:  J Pharmacol Methods       Date:  1985-11
View more
  77 in total

Review 1.  Myocardial preconditioning: basic concepts and potential mechanisms.

Authors:  S Okubo; L Xi; N L Bernardo; K Yoshida; R C Kukreja
Journal:  Mol Cell Biochem       Date:  1999-06       Impact factor: 3.396

Review 2.  Cardiac signal transduction.

Authors:  K H Lee; R J Hajjar; T Matsui; G Choukroun; T L Force; A Rosenzweig
Journal:  J Nucl Cardiol       Date:  2000 Jan-Feb       Impact factor: 5.952

Review 3.  Apoptosis in myocardial ischaemia and infarction.

Authors:  P A J Krijnen; R Nijmeijer; C J L M Meijer; C A Visser; C E Hack; H W M Niessen
Journal:  J Clin Pathol       Date:  2002-11       Impact factor: 3.411

Review 4.  Defining the success of cardiac gene therapy: how can nuclear imaging contribute?

Authors:  Norbert Avril; Frank M Bengel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-01-23       Impact factor: 9.236

5.  Mitochondrial Akt-regulated mitochondrial apoptosis signaling in cardiac muscle cells.

Authors:  Ching-Chieh Su; Jia-Ying Yang; Hsin-Ban Leu; Yumay Chen; Ping H Wang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-11-11       Impact factor: 4.733

6.  Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy.

Authors:  Q Li; B Li; X Wang; A Leri; K P Jana; Y Liu; J Kajstura; R Baserga; P Anversa
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

Review 7.  Death begets failure in the heart.

Authors:  Roger S-Y Foo; Kartik Mani; Richard N Kitsis
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

Review 8.  Signaling mechanisms in thyroid hormone-induced cardiac hypertrophy.

Authors:  Kaie Ojamaa
Journal:  Vascul Pharmacol       Date:  2009-12-11       Impact factor: 5.773

9.  Netrin-1 prevents ischemia/reperfusion-induced myocardial infarction via a DCC/ERK1/2/eNOS s1177/NO/DCC feed-forward mechanism.

Authors:  Jun Zhang; Hua Cai
Journal:  J Mol Cell Cardiol       Date:  2010-01-12       Impact factor: 5.000

10.  IGF-1 expression in infarcted myocardium and MGF E peptide actions in rat cardiomyocytes in vitro.

Authors:  Anastasia Stavropoulou; Antonios Halapas; Antigone Sourla; Anastassios Philippou; Efstathia Papageorgiou; Apostolos Papalois; Michael Koutsilieris
Journal:  Mol Med       Date:  2009-03-06       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.